Xeris Pharmaceuticals, Inc. (XERS) Social Stream
XERIS BIOPHARMA HOLDINGS INC (XERS) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering XERS.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-10-29 | 4 | $11 | $4 | $7.75 | $2.84 | 172.89% |
| 2021-11-11 | 4 | $11 | $4.25 | $7.312 | $2.84 | 157.46% |
| 2021-12-14 | 5 | $11 | $4.25 | $6.85 | $2.84 | 141.2% |
| 2021-12-31 | 5 | $11 | $5.4 | $7.08 | $2.84 | 149.3% |
| 2022-01-10 | 5 | $11 | $5.4 | $7.48 | $2.84 | 163.38% |
| 2022-02-01 | 5 | $11 | $6 | $7.6 | $2.84 | 167.61% |
| 2022-03-23 | 4 | $7 | $6 | $6.25 | $2.84 | 120.07% |
| 2022-05-12 | 5 | $7 | $6 | $6.3 | $2.84 | 121.83% |
| 2022-10-19 | 4 | $6.5 | $6 | $6.125 | $2.84 | 115.67% |
| 2022-10-21 | 5 | $6.5 | $4 | $5.7 | $2.84 | 100.7% |
| 2022-11-10 | 5 | $6.5 | $4 | $5.5 | $2.84 | 93.66% |
| 2023-03-09 | 5 | $6.5 | $4 | $5.3 | $2.84 | 86.62% |
| 2023-05-10 | 4 | $6 | $4 | $5 | $2.84 | 76.06% |
The Trend in the Analyst Price Target
Over the past 52 weeks, XERS's average price target has gone down $1.3.
Over the past 42 weeks, XERS's average upside potential has been 289.95%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-07-20 | 4 | 6.5 | 6 | 6.125 | 1.63 | 275.77% |
| 2022-10-19 | 4 | 6.5 | 6 | 6.125 | 1.23 | 397.97% |
| 2022-10-21 | 5 | 6.5 | 6 | 6.125 | 1.37 | 347.08% |
| 2023-03-09 | 5 | 6.0 | 4 | 5.000 | 1.25 | 300% |
| 2023-03-09 | 4 | 6.0 | 4 | 5.000 | 1.25 | 300% |
XERS Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1 | 4 | 0 | 0 | 0 | 0 | 4 |
The Trend in the Broker Recommendations
Over the past 52 weeks, XERS's average broker recommendation rating improved by 0.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for XERS as an investment opportunity.
- To contextualize these metrics, consider that out of all US stocks, XERIS BIOPHARMA HOLDINGS INC's average analyst price target is higher than 115.14% of them.
- XERS has a greater number of analysts covering the stock than 389.42% of all US stocks.
- To contextualize these metrics, consider that out of Healthcare stocks, XERIS BIOPHARMA HOLDINGS INC's variance in analysts' estimates is lower than -737.03% of them.
- XERIS BIOPHARMA HOLDINGS INC's upside potential (average analyst target price relative to current price) is higher than 1022.26% of stocks in the small market cap category.
Stocks similar to XERIS BIOPHARMA HOLDINGS INC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are VRCA, ITRM, and KNSA.
View All Top Stocks by Price Target
Make investment decisions regarding XERS using the data that counts. Try POWR Ratings for free.